熱門資訊> 正文
Viridian Therapeutics因2.25亿美元证券发行定价下滑
2024-09-12 14:12
- Viridian Therapeutics (NASDAQ:VRDN) shares dropped 2% after-hours on Wednesday after the biotechnology company priced an upsized underwritten public offering of common stock and preferred stock, comprising ~10.67M shares of common stock, issued at $18.75/share, and 20,000 shares of series B non-voting convertible preferred stock issued at $1,250.06250/share, which is convertible into ~1.33M shares of common stock.
- In addition, Viridian (VRDN) has granted the underwriters a 30-day option to purchase an additional 1.8 million shares of common stock at the public offering price.
- The gross proceeds from the offering are estimated to be $225M; net proceeds will be used to support the company's clinical development programs, as well as for working capital and general corporate purposes.
- All shares to be sold in the underwritten public offering are being offered by Viridian (VRDN).
- The offering is expected to close on or about September 13, 2024.
More on Viridian Therapeutics
- Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way
- Viridian Therapeutics: Key Inflection Points Ahead
- Viridian hits five-month high after trial data for lead asset (update)
- Seeking Alpha’s Quant Rating on Viridian Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
